Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Mia, Ståhle, Johanna M.U., Silvola, Sanna, Hellberg, Margreet, de Vries, Paul H.A., Quax, Jeffrey, Kroon, Petteri, Rinne, Alwin, de Jong, Heidi, Liljenbäck, Nina, Savisto, Anna, Wickman, Erik S.G., Stroes, Seppo, Ylä-Herttuala, Pekka, Saukko, Tommy, Abrahamsson, Knut, Pettersson, Juhani, Knuuti, Anne, Roivainen, Antti, Saraste

JACC: Basic to Translational Science |

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.

https://linkinghub.elsevier.com/retrieve/pii/S2452302X20300206